Is higher lymphocyte count a potential strategy for preventing chronic kidney disease in patients receiving long-term dasatinib treatment?

Table 1 Univariate analysis of patient characteristics between the two group

Variable	CKD Group (n = 8)	No CKD Group (n = 25)	p-value
Age (years)	60 (36–86)	43 (29–70)	0.008
Sex (male/female)	5/3	17/8	1.000
CML/Ph-ALL	6/2	24/1	0.139
Serum creatinine level (mg/dL) at baseline	0.93 (0.55–1.02)	0.78 (0.53–1.12)	0.435
eGFR (mL/min/1.73 m²) at baseline	68 (61–77)	80 (55–103)	0.003
Hypertension	2	2	0.062
Diabetes mellitus	0	4	1.000
Common dasatinib-related adverse events^a)	5	13	1.000
Pleural effusion	3	7	0.623
Lymphocytosis	1	17	0.012
Lymphopenia	2	3	0.574
Concomitant potential nephrotoxic agents	3	6	0.651
Concomitant use of diuretics	3	8	0.420
Median lymphocyte count (/μL)	2025 (780–3413)	2760 (1089–6200)	0.089
Maximal lymphocyte count (/μL)	3279 (1246–4183)	4813 (2075–10,545)	0.001
Minimum lymphocyte count (/μL)	896 (390–2136)	1184 (484‒2288)	0.127
Maximal-baseline lymphocyte count ratio	1.5 (1.0–3.8)	2.2 (0.8–9.3)	0.176
Median NLR	1.59 (0.75–4.58)	1.21 (0.40–2.22)	0.136
History of TKI(s) prior to dasatinib	6	14	0.431
(Imatinib/nilotinib/Both)	(3/1/2)	(8/3/3)

Abbreviations: CKD chronic kidney disease, CML chronic myeloid leukemia, eGFR estimated glomerular filtration rate, NLR neutrophil–lymphocyte count ratio, Ph-ALL Philadelphia chromosome-positive acute lymphoblastic leukemia, TKI tyrosine kinase inhibitor
¹Pleural effusion, colitis, and pulmonary hypertension were included as common dasatinib-related adverse events

ISSN: 2055-0294